The expanding applications of non-myeloablative stem cell transplantation

Pediatric Transplantation

Volumn 7, Issue SUPPL. 3, 2003, Pages 95-100

  Spitzer, Thomas R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Applications; Non myeloblative; Stem cell transplantation

Indexed keywords

ALLOGRAFT; CHIMERA; CLINICAL TRIAL; CONFERENCE PAPER; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MORBIDITY; MORTALITY; SOLID TUMOR; STEM CELL TRANSPLANTATION;

ANIMALS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MODELS, ANIMAL; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION TOLERANCE;

EID: 0037222761     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.7.s3.15.x     Document Type: Conference Paper

References (27)

1. GIRALT S, ESTEY E, ALBITAR M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997: 89: 4531-4536.
2. SLAVIN S, NAGLER A, NAPARSTEK E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998: 91: 756-763.
3. SYKES M, PREFFER F, SAIDMAN SL, et al. Mixed Lymphohematopoietic chimerism is achievable following non-myeloablative therapy and HLA-mismatched donor marrow transplantation. Lancet 1998: 353: 1755-1759.
4. CHILDS R, CLAVE E, CONTENTIN N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T cell chimerism precedes alloimmune responses. Blood 1999: 94: 3234-3241.
5. SPITZER T, McAFEE S, SACKSTEIN R, et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000: 6: 309-320.
6. SHARABI Y, SACHS DH. Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen. J Exp Med 1989: 169: 493.
7. PELOT MR, PEARSON DA, SWENSON K, et al. Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease. Biol Blood Marrow Transplant 1999: 5: 133-143.
8. PRIGOZHINA T, GUREVITCH O, SLAVIN S. Nonmyeloablative conditioning to induce bilateral tolerance after allogeneic bone marrow transplantation in mice. Exp Hematol 1999: 27: 1503-1510.8.
9. SYKES M, SZOT GL, SWENSON K, PEARSON DA. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med 1997: 3: 783-787.
10. STOREK J, DAWSON M, STORER B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001: 97: 3380-3389.
11. MCSWEENEY P, NIEDERWIESER P, SHIZURU J, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001: 97: 3390-3400.
12. BRANCO L, BARREN P, MAO S, et al. Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells. Transplantation 1999: 68: 1588-1596.
13. ZAUCHA J, YU C, LOTHROP CJ, et al. Severe canine hereditary hemolytic anemia treated by nonmyeloablative marrow transplantation. Biol Blood Marrow Transplant 2001: 7: 14-24.
14. WOOLFREY A, NASH R, FRANGOUL H, et al. Nonmyeloablative transplant regimen used for induction of multilineage allogeneic hematopoietic mixed donor-host chimerism in patients with T cell immunodeficiencies. Blood 1998: 92: 520a.
15. HORWITZ M, BARRETT A, BROWN M, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T cell-depleted hematopoietic allograft. N Engl J Med 2001: 344: 881-888.
16. WALTERS M, PATIENCE M, LEISENRING A, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996: 335: 369-376.
17. KRISHNAMURTI L, BLAZAR B, WAGNER J. Bone marrow transplantation without myeloablation for sickle cell disease. N Engl J Med 2001: 344: 68-74.
18. LUCARELLI G, GALIMBERTI M, POLCHI P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990: 322: 417-421.
19. MENTZER W, COWAN M. Bone marrow transplantation for beta-thalassemia: The University of California San Francisco experience. J Pediatr Hematol Oncol 2000: 22: 598-601.
20. CHILDS R, CHERNOFF A, CONTENTIN N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000: 343: 750-758.
21. OR R, ACKERSTEIN A, NAGLER A, et al. Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: A clinical pilot study. Cytokines Cell Mol Ther 1998: 4: 1-6.
22. UENO N, RONDON G, MIRZA N, et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998: 16: 986-993.
23. YIN J, JOWITT S. Resolution of immune-mediated diseases following allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 1992: 91: 31-33.
24. COLSON YL, ZADACH K, NALESNIK M, ILDSTAD ST. Mixed allogeneic chimerism in the rat. Donor-specific transplantation tolerance without chronic rejection for primarily vascularized cardiac allografts. Transplantation 1995: 60: 971-980.
25. KAWAI T, COSIMI AB, COLVIN RB, et al. Mixed allogeneic chimerism and renal allograft tolerence in cynomologous monkeys. Transplantation 1995: 59: 256
26. MADSEN JC, YAMADA K, ALLAN JS, et al. Transplantation tolerance prevents cardiac graft vasculopathy in major histocompatibility complex class I-disparate miniature swine. Transplantation 1998: 65: 304-313.
27. WEKERLE T, SYKES M. Mixed chimerism and transplantation tolerance. Annu Rev Med 2001: 52: 353-370.